Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development

Reuters08-18

Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development

Klotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2560402907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560402907","market":"fut","top_or_hot":-1,"title":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a>, a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKlotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-18 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a>, a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3LV5ZQ:1","article_id":"2560402907","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560402907","pubTimestamp":1755520268,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development. Klotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis . This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KLTO":"Klotho Neurosciences, Inc."},"translate_title":"Klotho Neuroscience Inc.获得FDA ALS治疗孤儿药指定，推进基于Klotho的治疗开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLTO":0.9},"content_text":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    \n\nKlotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560402907","isCrawlerRequest":true}